Global Clinical
Mass Spectrometry Market, by Product Type (Gas chromatography–mass
spectrometry (GC-MS) instrument, Liquid chromatography–mass spectrometry
(LC-MS) instrument, MALDI-TOF mass spectrometer, Capillary electrophoresis–mass
spectrometry, and Ion mobility spectrometry-mass spectrometry), by Application
(Clinical Testing, Proteomics, and Drug discovery), by End User (Research
Laboratories, Diagnostic Laboratories, and Hospitals), and By Region (North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to
be valued at US$ 697.2 million in 2019, and is expected to exhibit a
CAGR of 5.5% over the forecast period (2019 - 2027). Increasing investments in
R&D activities by pharmaceutical companies are driving growth of the global
clinical mass spectrometry market. Mass spectrometry continues to play a
prominent role in laboratory medicine. For instance, in 2019, Biotage AB
collaborated with Shandong Yingsheng Biotechnology Co., Ltd to focus on
research, production and selling in vitro diagnostic reagents and medical
equipment, building a genetic detection platform and mass spectrometry
detection platform around metabolomics and genetics.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/193
As a part of the collaboration,
Biotage and Yingsheng agreed to develop clinical mass spectrometry applications
in China, where Biotage will provide systems and consumables through its
analytical chemistry portfolio and Yingsheng will sell it with its brand name.
Moreover, use of clinical mass spectrometry in laboratory developed tests
(LDTs) is driving growth of this market. Properties such as sensitive
analytical capabilities and enhancements continue to bring the technology to
the edge of new scientific discovery and research applications. Matrix-assisted
laser desorption/ionization - time of flight (MALDI-TOF) have wide application
in microbiology laboratories. MALDI-TOF systems that have been designated as
medical devices that support FDA-cleared or CE-marked assays. Assays that have
received FDA clearance or CE-marking over the last few years have largely
revolved around microbiological identifications with MALDI-TOF. These assays
are different from the majority of the clinical mass spectrometry market, which
is covered by laboratory developed tests (LDTs).
Browse 43 Market Data Tables and
33 Figures spread through 169 Pages and in-depth TOC on "Global Clinical
Mass Spectrometry Market, by Product Type (Gas chromatography–mass spectrometry
(GC-MS) instrument , Liquid chromatography–mass spectrometry (LC- MS)
instrument, MALDI-TOF mass spectrometer, Capillary electrophoresis–mass
spectrometry, and Ion mobility spectrometry-mass spectrometry), by Application
(Clinical Testing, Proteomics, and Drug discovery), by End User (Research
Laboratories, Diagnostic Laboratories, and Hospitals), and By Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Global
Forecast to 2027"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/clinical-mass-spectrometry-market-193
Key Takeaways of the Clinical
Mass Spectrometry Market:
The global clinical mass
spectrometry market is expected to exhibit a CAGR of 5.5% over the forecast
period (2019 – 2027), owing to technological advancements in mass spectrometry
and increasing adoption in laboratory developed tests.
Among region, Asia Pacific is
expected to witness significant growth in the global clinical mass spectrometry
market over the forecast period, owing to high R&D investment by
pharmaceutical companies.
Gas chromatography – mass
spectrometry (GC-MS) instrument segment held a dominant position in clinical
mass spectrometry market, owing to high adoption of this technology by players
operating in the market.
Major players operating in the
global clinical mass spectrometry market include Bruker Corporation, Kore
Technology Limited, Bergman Messgerate Entwicklung KG, Mass Spectrometry
Instruments (MSI), Thermo Fisher Scientific Inc., Agilent Technologies, and
Danaher Corporations.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/193
About
Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment